Companies › GigaGen
2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GIGA-564 | – | Phase 1 | Advanced or Metastatic Solid Tumor Malignancies | Nov 2027 |
| GIGA-2339 | – | Phase 1 | Hepatitis B Virus Infection | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06258304 | GIGA-564 | Phase 1 | Advanced or Metastatic Solid Tumor Malignancies | Oncology | Nov 2027 |
| NCT07024641 | GIGA-2339 | Phase 1 | Hepatitis B Virus Infection | Infectious disease | Nov 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.